All In Biotech

Drug Trial Radar · NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

616

Planned (sponsor's estimate)

Start

Jan 18, 2024

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Conditions

  • Non-Small Cell Lung Cancer, NSCLC
  • KRAS, NRAS, HRAS-mutated NSCLC
  • KRAS G12C-mutated Solid Tumors, Lung Cancer
  • Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
  • RAS G12D-mutated NSCLC

Interventions

  • RMC-6291Drug

    Oral tablet

  • RMC-6236Drug

    Oral tablet

  • PembrolizumabDrug

    IV Infusion

  • CisplatinDrug

    IV Infusion

  • CarboplatinDrug

    IV Infusion

  • PemetrexedDrug

    IV infusion

  • RMC-9805Drug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Up to 5 years
  2. Dose limiting toxicitiesTime frame: 21 days

Locations

98 sites in 13 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • City of Hope - Duarte

    Duarte, California · Active not recruiting

  • City of Hope - Lennar

    Irvine, California · Active not recruiting

  • University of California Los Angeles

    Los Angeles, California · Active not recruiting

  • UC Davis, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of California, San Diego Moores Cancer Center

    San Diego, California · Recruiting

  • UCSF Medical Center - Mission Bay

    San Francisco, California · Recruiting

  • Stanford University - Stanford Cancer Institute

    Stanford, California · Recruiting

  • Kaiser Permanente

    Vallejo, California · Active not recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Boca Raton Clinical Research Associates

    Plantation, Florida · Recruiting

  • Cancer Specialists of North Florida

    Saint Augustine, Florida · Active not recruiting

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

    Detroit, Michigan · Active not recruiting

  • Intermountain Health - St. Vincent Frontier Cancer Center

    Billings, Montana · Active not recruiting

  • Nebraska Cancer Specialist

    Grand Island, Nebraska · Recruiting

  • New York University Langone Health

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Active not recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Clinical Research Alliance

    Westbury, New York · Active not recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Baptist Medical Center

    Memphis, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Active not recruiting

  • Chris O'Brien Lifehouse Hosptial

    Camperdown, New South Wales, Australia · Active not recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Active not recruiting

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Active not recruiting

  • Monash Health

    Clayton, Victoria, Australia · Active not recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Active not recruiting

  • Wiener Gesundheitsverbund - Klinik Floridsdorf

    Vienna, Austria · Active not recruiting

  • Universitätsklinikum St. Pölten

    Sankt Pölten, Austria, Austria · Active not recruiting

  • Nemocnice AGEL Novy Jicin a.s

    Nový Jičín, Czech Republic, Czechia · Active not recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital, Department of Oncology

    Odense, Denmark · Recruiting

  • Institut de Cancerologie de Ouest (ICO) - Angers

    Angers, France · Recruiting

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.